Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UN37
UPID:
VPS4A_HUMAN
Alternative names:
Protein SKD2; VPS4-1
Alternative UPACC:
Q9UN37; B2RCB7; Q8TF07; Q9UI03; Q9Y582
Background:
Vacuolar protein sorting-associated protein 4A (VPS4A), also known as Protein SKD2 and VPS4-1, plays a crucial role in the endosomal multivesicular bodies (MVB) pathway. It is essential for the disassembly of membrane-associated ESCRT-III assemblies, aiding in the regulation of endosome size, primary cilium organization, and mitotic spindle organization. VPS4A is also pivotal in cytokinesis, chromosome segregation, and nuclear envelope sealing.
Therapeutic significance:
The involvement of VPS4A in CIMDAG syndrome, characterized by developmental delay, intellectual disability, and hematologic abnormalities, underscores its therapeutic significance. Understanding the role of VPS4A could open doors to potential therapeutic strategies for treating CIMDAG syndrome and improving patient outcomes.